Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given an average rating of “Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $21.60.

Several equities research analysts recently weighed in on the company. Morgan Stanley decreased their target price on Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. D. Boral Capital reissued a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 18th. JonesTrading reduced their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, March 19th. Finally, Stifel Nicolaus upped their target price on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $11.33 on Friday. The stock has a market cap of $1.45 billion, a PE ratio of -35.41 and a beta of 0.94. The stock’s fifty day moving average is $11.14 and its two-hundred day moving average is $11.09. Trevi Therapeutics has a 1-year low of $4.85 and a 1-year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04. On average, research analysts expect that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

Large investors have recently bought and sold shares of the stock. Vivo Capital LLC boosted its position in shares of Trevi Therapeutics by 28.7% in the 2nd quarter. Vivo Capital LLC now owns 4,487,903 shares of the company’s stock valued at $24,549,000 after purchasing an additional 1,000,000 shares during the period. Prudential Financial Inc. purchased a new position in Trevi Therapeutics during the 2nd quarter worth approximately $1,238,000. Jefferies Financial Group Inc. acquired a new position in Trevi Therapeutics during the second quarter worth approximately $301,000. Flputnam Investment Management Co. increased its position in Trevi Therapeutics by 1,105.4% during the third quarter. Flputnam Investment Management Co. now owns 1,048,102 shares of the company’s stock worth $9,590,000 after buying an additional 961,150 shares during the period. Finally, Tejara Capital Ltd lifted its stake in Trevi Therapeutics by 81.8% in the second quarter. Tejara Capital Ltd now owns 326,395 shares of the company’s stock valued at $1,785,000 after buying an additional 146,879 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.